deltatrials
Terminated PHASE2 NCT00041574

Hospital-Based Program for Treatment of Severe Cardiopulmonary Disease With Inhaled Nitric Oxide

Development of a Hospital-Based Home Program for the Use of Inhaled Nitric Oxide in the Chronic Management of Severe Cardiopulmonary Diseases

Sponsor: Mallinckrodt

Conditions Cardiac Transplant Lung Disease Lung Transplant Pulmonary Hypertension Sickle Cell Disease
Interventions Inhaled Nitric Oxide
Updated 6 times since 2017 Last updated: Sep 8, 2016 Started: Apr 30, 2002 Primary completion: Dec 31, 2005 Completion: Dec 31, 2005

This PHASE2 trial investigates Cardiac Transplant and Lung Disease and is currently terminated or withdrawn. Mallinckrodt leads this study, which shows 6 recorded versions since 2002 — indicating limited longitudinal coverage. Heart and vascular conditions benefit from the kind of long-term tracking this trial provides.

Change History

6 versions recorded

  1. Sep 2024 — Present [monthly]

    Terminated PHASE2

  2. Jul 2024 — Sep 2024 [monthly]

    Terminated PHASE2

  3. Jan 2021 — Jul 2024 [monthly]

    Terminated PHASE2

  4. Jun 2018 — Jan 2021 [monthly]

    Terminated PHASE2

  5. Feb 2017 — Jun 2018 [monthly]

    Terminated PHASE2

▶ Show 1 earlier version

  1. Jan 2017 — Feb 2017 [monthly]

    Terminated PHASE2

    First recorded

Apr 2002

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:
  • Mallinckrodt
Data source: Mallinckrodt

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

  • • Denver, United States
  • • Providence, United States